Diagnostic and Prognostic Value of Circulating MicroRNAs for Esophageal Squamous Cell Carcinoma: a Systematic Review and Meta-analysis

Yao, Cheng‐Bao; Liu, Haining; Wu, Hao; Chen, Yanjie; Li, Yu; Fāng, Yīng; Shen, Xin; Liu, Taotao

doi:10.7150/jca.25351

Cited by 8 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, such small molecules have been investigated as serum markers of EC [15][16][17]. A recent meta-analysis, including 35 studies investigating plasma or serum miRNAs of ESCC patients [33], concluded that circulating miRNAs could distinguish ESCC patients from controls with a pooled sensitivity of 79.4% (95% CI, 76.5-82.0%), specificity of 77.9% (95% CI, 74.6-80.8%), and AUC of 0.86 (95% CI, 0.82-0.88). Another meta-analysis exclusively focusing on Asian populations found that miRNAs could distinguish patients with ESCC from controls with 77.7% pooled sensitivity (95% CI, 74.2-80.9%), 80.9% specificity (95% CI, 76.6-84.6%), and AUC of 0.86 (95% CI, 0.83-0.89) [34].…”

Section: Blood Biomarkers Of Esophageal Squamous Cell Carcinomamentioning

confidence: 99%

Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence

Visaggi

Barberio

Ghisa

et al. 2021

Cancers

View full text Add to dashboard Cite

Esophageal cancer (EC) is the seventh most common cancer and the sixth cause of cancer death worldwide. Histologically, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) account for up to 90% and 20% of all ECs, respectively. Clinical symptoms such as dysphagia, odynophagia, and bolus impaction occur late in the natural history of the disease, and the diagnosis is often delayed. The prognosis of ESCC and EAC is poor in advanced stages, being survival rates less than 20% at five years. However, when the diagnosis is achieved early, curative treatment is possible, and survival exceeds 80%. For these reasons, mass screening strategies for EC are highly desirable, and several options are currently under investigation. Blood biomarkers offer an inexpensive, non-invasive screening strategy for cancers, and novel technologies have allowed the identification of candidate markers for EC. The esophagus is easily accessible via endoscopy, and endoscopic imaging represents the gold standard for cancer surveillance. However, lesion recognition during endoscopic procedures is hampered by interobserver variability. To fill this gap, artificial intelligence (AI) has recently been explored and provided encouraging results. In this review, we provide a summary of currently available options to achieve early diagnosis of EC, focusing on blood biomarkers, advanced endoscopy, and AI.

show abstract

Section: Blood Biomarkers Of Esophageal Squamous Cell Carcinomamentioning

confidence: 99%

Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence

Visaggi

Barberio

Ghisa

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…The reported expression profiles of various circulating miRNAs in ESCC are inconsistent. 18 19 20 21 22 26 In the present study, we selected four miRNAs and investigated their expression levels in the plasma of ESCC patients based on previously published literature. We found that plasma miR-21, miR-31, and miR-375 could be potential biomarkers for ESCC diagnosis.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients

et al. 2022

View full text Add to dashboard Cite

Background Patients with esophageal squamous cell carcinoma (ESCC) have a poor prognosis and there are no effective clinical biomarkers. Recently, stable microRNAs detected in the blood have been suggested as potential biomarkers in various cancers. Therefore, we investigated whether plasma microRNAs could be feasible biomarkers for ESCC. Methods Peripheral blood samples were obtained from 16 healthy volunteers and 66 ESCC patients before treatment between May 2016 and April 2021. Plasma miR-18b, miR-21, miR-31, and miR-375 expression levels were measured using reverse transcription-quantitative polymerase chain reaction. Results Compared with those in healthy controls, the expression levels of plasma miR-21 were significantly higher ( P = 0.022) and those of plasma miR-31 and miR-375 were significantly lower in ESCC patients (both P < 0.001). Plasma miR-18b expression levels increased in ESCC patients, but the difference was not significant ( P = 0.164). The sensitivities and specificities of miR-21, miR-31, and miR-375 for differentiating ESCC patients from healthy controls were 87.5% and 61.9%, 87.5% and 98.4%, and 87.5% and 100%, respectively. There was no difference in expression levels of plasma miR-21, miR-31, and miR-375 according to clinicopathological characteristics of sex, age, tumor size and location, histologic grade, and tumor-node-metastasis stage. Conclusion Our study demonstrated that plasma miR-21, miR-31, and miR-375 could be potential biomarkers for the diagnosis of ESCC. Particularly, plasma miR-31 and miR-375 showed high sensitivity and specificity for differentiating ESCC patients from healthy controls.

show abstract

“…An I 2 less than 25% represents potentially unimportant heterogeneity; an I 2 of 25% to 50% represents moderate heterogeneity; an I 2 of 50% to 75% represents substantial heterogeneity, and an I 2 of 75% to 100% represents high heterogeneity 10 . A fixed-effect model was used to pool the data if I 2 < 50%, 11 whereas a random-effect model was used if I 2 ≥ 50%. Sensitivity and subgroup analyses were performed to explore the possible sources of heterogeneity if I 2 ≥ 50% 12 .…”

Section: Methodsmentioning

confidence: 99%

Comparison of Donor Site Morbidity Between Anterolateral Thigh and Radial Forearm Free Flaps for Head and Neck Reconstruction: A Systematic Review and Meta-Analysis

Niu

Tao

et al. 2021

Journal of Craniofacial Surgery

View full text Add to dashboard Cite

This meta-analysis aimed to provide an up-to-date comparison of donor site morbidity (DSM) between patients who underwent head and neck reconstruction with Anterolateral thigh (ALT) and radial forearm free (RFF) flaps. We searched the PubMed, Web of Science, EMBASE, and Cochrane Library databases to identify studies that compared DSM between ALT and RFF patients. Study quality was assessed using the Newcastle-Ottawa Scale. The pooled odds ratio (OR) of each DSM between ALT and RFF patients was estimated using a random-or fixed-effect model depending on the degree of interstudy heterogeneity. Sensitivity and subgroup analyses were performed if substantial heterogeneity was detected. Eighteen cohort studies with 1,018 patients (535 ALT and 483 RFF patients) were included. Compared with RFF, ALT were associated with lower risks of wound dehiscence (OR ¼ 0.2, 95%CI: 0.10-0.42, P < 0.01), strength impairment (OR ¼ 0.18, 95%CI: 0.07-0.47, P < 0.01), and movement impairment (OR ¼ 0.19, 95%CI:0.07-0.49, P < 0.01). A subgroup analysis showed that ALT were associated with a lower risk of donor site numbness among patients undergoing tongue reconstruction (OR ¼ 0.05, 95%CI: 0.01-0.25, P < 0.01), but not among all patients undergoing head and neck reconstruction. The pooled ORs of other DSMs demonstrated no significant difference between ALT and RFF patients. ALT are superior to RFF for head and neck reconstruction in terms of donor site wound dehiscence, strength impairment, movement impairment, and for tongue reconstruction specifically in terms of donor site numbness. No significant differences in the incidence of donor site hematoma/seroma, infection, or dissatisfaction with donor site appearance were identified between ALT and RFF patients.

show abstract

Diagnostic and Prognostic Value of Circulating MicroRNAs for Esophageal Squamous Cell Carcinoma: a Systematic Review and Meta-analysis

Cited by 8 publications

References 56 publications

Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence

Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence

MicroRNA Expression in Plasma of Esophageal Squamous Cell Carcinoma Patients

Comparison of Donor Site Morbidity Between Anterolateral Thigh and Radial Forearm Free Flaps for Head and Neck Reconstruction: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About